ATE401082T1 - Medizinische zusammensetzung zur prävention oder behandlung von zerebrovaskulären störungen - Google Patents
Medizinische zusammensetzung zur prävention oder behandlung von zerebrovaskulären störungenInfo
- Publication number
- ATE401082T1 ATE401082T1 AT02751784T AT02751784T ATE401082T1 AT E401082 T1 ATE401082 T1 AT E401082T1 AT 02751784 T AT02751784 T AT 02751784T AT 02751784 T AT02751784 T AT 02751784T AT E401082 T1 ATE401082 T1 AT E401082T1
- Authority
- AT
- Austria
- Prior art keywords
- drug
- components
- prevention
- treatment
- medical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001274846 | 2001-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE401082T1 true ATE401082T1 (de) | 2008-08-15 |
Family
ID=19099815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02751784T ATE401082T1 (de) | 2001-09-11 | 2002-07-30 | Medizinische zusammensetzung zur prävention oder behandlung von zerebrovaskulären störungen |
Country Status (6)
Country | Link |
---|---|
US (1) | US20040242565A1 (de) |
EP (1) | EP1426051B1 (de) |
JP (1) | JP4194095B2 (de) |
AT (1) | ATE401082T1 (de) |
DE (1) | DE60227679D1 (de) |
WO (1) | WO2003024457A1 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040097583A1 (en) * | 2002-02-14 | 2004-05-20 | Hans-Jochen Lang | Use of inhibitors of the sodium/hydrogen exchanger for the treatment of thrombotic and inflammatory disorders |
US20050182042A1 (en) * | 2002-05-17 | 2005-08-18 | Feldman David L. | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
US20040168951A1 (en) * | 2003-02-27 | 2004-09-02 | Mackie Robert W. | Method and system for self administration of medications |
US20040266755A1 (en) * | 2003-05-29 | 2004-12-30 | Schering Aktiengesellschaft | Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine |
US20080242660A1 (en) * | 2004-01-29 | 2008-10-02 | Asahi Kasei Pharma Corporation | Therapeutic Agent for Vasospasm Accompanying Bypass Operation |
FR2894825B1 (fr) * | 2005-12-21 | 2010-12-03 | Servier Lab | Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent |
FR2894826B1 (fr) * | 2005-12-21 | 2010-10-22 | Servier Lab | Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent |
CA2674542C (en) * | 2006-12-21 | 2012-10-09 | Catholic Healthcare West | Neuroprotection by blood flow stabilization |
US20100093810A1 (en) * | 2007-10-05 | 2010-04-15 | Alzheimer's Institute Of America, Inc. | Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis |
DK2214666T3 (da) * | 2007-10-05 | 2014-01-27 | Alzheimer S Inst Of America Inc | Fremgangsmåde til reducering af amyloid-afsætning, amyloid-neurotoksicitet og mikrogliose med (-)-nilvadipin-enantiomer |
WO2009046338A1 (en) * | 2007-10-05 | 2009-04-09 | Roskamp Research Llc | Method for increasing cerebral blood flow with (+)-nilvadipine enantiomer |
CN101969955A (zh) * | 2008-01-31 | 2011-02-09 | 莫纳什大学 | 治疗血栓栓塞疾病的方法 |
FR2927538B1 (fr) * | 2008-02-14 | 2010-02-19 | Servier Lab | Association d'un inhibiteur du courant if sinusal et d'un beta-bloquant. |
ES2330404B1 (es) * | 2008-05-19 | 2010-09-22 | Universidad De Barcelona | Solucion acuosa para la preservacion de tejidos y organos. |
KR101721068B1 (ko) * | 2015-01-30 | 2017-03-29 | 고려대학교 산학협력단 | 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3583287D1 (de) * | 1984-12-27 | 1991-07-25 | Asahi Chemical Ind | Substituierte isochinolinsulfonyl-verbindungen. |
AU4246793A (en) * | 1992-05-13 | 1993-12-13 | Alcon Laboratories, Inc. | Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents |
DE4430128A1 (de) * | 1994-08-25 | 1996-02-29 | Hoechst Ag | Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen |
WO1996025933A2 (en) * | 1995-02-22 | 1996-08-29 | Takeda Chemical Industries, Ltd. | Use of vinyl carboxylic acid compounds for the treatment or prevention of transient ischaemic attacks |
US5827832A (en) * | 1995-03-06 | 1998-10-27 | Interneuron Pharmaceuticals, Inc. | Method of protecting brain tissue from cerebral infarction subsequent to ischemia |
JPH11292787A (ja) * | 1995-08-15 | 1999-10-26 | Asahi Chem Ind Co Ltd | 生理活性ペプチドを含有する経粘膜投与製剤 |
DE69724108T2 (de) * | 1996-02-02 | 2004-06-09 | D.Western Therapeutics Institute, Nagoya | Isochinolinderivate und arzneimittel |
JPH107590A (ja) * | 1996-06-24 | 1998-01-13 | Chugai Pharmaceut Co Ltd | 脳循環障害後遺症または脳虚血後の脳神経障害の治療剤 |
AU2001278045B2 (en) * | 2000-07-27 | 2006-08-03 | Pharmacia Corporation | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
JP2002226374A (ja) * | 2001-01-31 | 2002-08-14 | Asahi Kasei Corp | 狭心症治療用組成物 |
-
2002
- 2002-07-30 JP JP2003528553A patent/JP4194095B2/ja not_active Expired - Fee Related
- 2002-07-30 EP EP02751784A patent/EP1426051B1/de not_active Expired - Lifetime
- 2002-07-30 AT AT02751784T patent/ATE401082T1/de not_active IP Right Cessation
- 2002-07-30 DE DE60227679T patent/DE60227679D1/de not_active Expired - Lifetime
- 2002-07-30 WO PCT/JP2002/007712 patent/WO2003024457A1/ja active IP Right Grant
- 2002-07-30 US US10/488,699 patent/US20040242565A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1426051A4 (de) | 2005-06-15 |
US20040242565A1 (en) | 2004-12-02 |
JPWO2003024457A1 (ja) | 2004-12-24 |
EP1426051B1 (de) | 2008-07-16 |
EP1426051A1 (de) | 2004-06-09 |
DE60227679D1 (de) | 2008-08-28 |
JP4194095B2 (ja) | 2008-12-10 |
WO2003024457A1 (fr) | 2003-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE401082T1 (de) | Medizinische zusammensetzung zur prävention oder behandlung von zerebrovaskulären störungen | |
CY1120591T1 (el) | Ιατρικη συνθεση για βελτιωση λειτουργιας εγκεφαλου | |
MXPA04009784A (es) | Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas. | |
RU99115750A (ru) | Новые соединения с анальгезирующим действием | |
ATE445405T1 (de) | Vorbeugung und behandlung von oxidativer-stress- erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen | |
DE69912808D1 (de) | Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel | |
DE60325074D1 (de) | Kristall für ein orales, festes arzneimittel, und ein orales, festes arnzeimittel zur behandlung von dysurie, das diesen enthält | |
ATE556712T1 (de) | A2a antagonisten zur behandlung von motorischen störungen | |
EA200601281A1 (ru) | Азабензофуранзамещенные тиомочевины; ингибиторы репликации вирусов | |
DK499385D0 (da) | Piperazinforbindelser | |
DE602004020685D1 (de) | Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3-cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i-epsilon | |
ATE325610T1 (de) | Xanthinderivative zur behandlung von hirnischämie | |
ATE187642T1 (de) | Verwendund von norastemizol zur behandlung der allergischen rhinitis | |
ES2100222T3 (es) | Derivados del acido aminoalcansulfonico y compuestos farmaceuticos a utilizar para prevenir o tratar afecciones cardiacas. | |
DE69426855D1 (de) | Verwendung von 2-phenyl-3-aroylbenzothiophen Derivaten zur Herstellung eines Medikaments zur Hemmung des Knorpelabbaus | |
ATE161725T1 (de) | Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina | |
DE60137442D1 (de) | 5-amidino-2-hydroxybenzolsulfonamidderivate, pharmazeutischen zusammensetzungen, die diese verbindungen enthalten, und zwischenprodukte zu deren herstellung | |
DE69500673D1 (de) | Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind | |
CA2534634A1 (en) | Azolidinecarbonitriles and their use as dpp-iv inhibitors | |
ATE284684T1 (de) | Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut | |
DE60123528D1 (de) | Verwendung eines Mittels zur Verbesserung der Astrozytenfunktion zur Behandlung von Parkinsons Krankheit | |
ZA891769B (en) | Heterocyclic compounds | |
ATE272403T1 (de) | Therapeutisches mittel zur behandlung von dermatitis | |
ATE511395T1 (de) | Mittel zur behandlung von glomerulopathie | |
ATE431148T1 (de) | Verwendung von cyclischen bioisosteren von purin- system-derivaten zur behandlung von erkrankungen durch störungen der nitrergen und dopaminergen systeme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |